| Literature DB >> 35745158 |
Daniel de Luis Roman1, David Primo1, Olatz Izaola1, Rocio Aller1.
Abstract
In cross-sectional studies, the genetic variant rs662799 of the APOA5 gene is associated with high serum triglyceride concentrations, and in some studies, the effect of short-term dietary interventions has been evaluated. The aim of the present investigation was to evaluate the role of this genetic variant in metabolic changes after the consumption of a low-calorie diet with a Mediterranean pattern for 9 months. A population of 269 Caucasian obese patients was recruited. Adiposity and biochemical parameters were measured at the beginning (basal level) and after 3 and 9 months of the dietary intervention. The rs662799 genotype was assessed with a dominant analysis (TT vs. CT + CC). The APOA5 variant distribution was: 88.1% (n = 237) (TT), 11.5% (n = 31) (TC) and 0.4% (n = 1) (CC). There were significant differences only in triglyceride levels at all times of the study between the genotype groups. After 3 and 9 months of dietary intervention, the following parameters improved in both genotype groups: adiposity parameters, systolic pressure, total cholesterol, LDL cholesterol, leptin, adiponectin and the leptin/adiponectin ratio. The intervention significantly decreased insulin levels, HOMA-IR and triglyceride levels in non-C allele carriers (Delta 9 months TT vs. TC + CC). i.e., insulin levels (delta: -3.8 + 0.3 UI/L vs. -1.2 + 0.2 UI/L; p = 0.02), HOMA-IR levels (delta: -1.2 + 0.2 units vs. -0.3 + 0.1 units; p = 0.02), triglyceride levels (delta: -19.3 + 4.2 mg/dL vs. -4.2 + 3.0 mg/dL; p = 0.02). In conclusion, non-C allele carriers of rs662799 of the APOA5 gene showed a decrease of triglyceride, insulin and HOMA-IR levels after consuming a low-calorie diet with a Mediterranean pattern; we did not observe this effect in C allele carriers, despite a significant weight loss.Entities:
Keywords: ApoA5 gene; low-calorie diet; rs662799; triglycerides
Mesh:
Substances:
Year: 2022 PMID: 35745158 PMCID: PMC9231022 DOI: 10.3390/nu14122427
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Average daily intakes and physical activity determined at three times (basal and 3 and 9 months after the intervention) (mean ± SD).
| TT ( | TC + CC ( | |||||
|---|---|---|---|---|---|---|
| 0 Time | 3 Months | 9 Months | 0 Time | 3 Months | 9 Months | |
| Calorie intake (kcal/day) | 1728.9 + 210.8 | 1012.1 + 21.1 * | 1008.1 + 13.1 * | 1823.9 + 129.1 | 1010.1 + 18.1 * | 1001.9 + 12.1 * |
| Carbohydrate intake (g/day) (PTC%) | 207.8 + 51.9 | 137.5 + 20.1 $ | 130.1 + 18.1 $ | 218.1 + 41.1 | 133.1 + 19.1 $ | 130.9 + 12.1 $ |
| Fat intake (g/day) (PTC%) | 58.9 + 10.3 (30.6%) | 31.1 + 8.1 # (26.7%) | 32.2 + 5.1 # (26.9%) | 62.4 + 8.3 (30.8%) | 30.2 + 4.3 # (26.9%) | 31.1 + 5.1 # (27.4%) |
| Protein intake (g/day) (PTC%) | 88.6 + 14.1 (20.5%) | 50.6 + 7.3 & (20.0%) | 51.9 + 7.1 & (20.2%) | 92.9 + 10.1 (22.4%) | 51.2 + 6.9 & (20.5%) | 52.3 + 6.0 & (21.0%) |
| Saturated Fat intake (g/day) (PFC%) | 36.2 + 6.0 | 6.1 + 4.9 ** | 6.4 + 4.0 ** | 37.8 + 5.1 | 5.9 + 2.2 | 5.3 + 1.1 |
| Monounsaturated Fat intake (g/day) (PFC%) | 15.2 + 3.1 | 21.3 + 2.9 $$ | 22.1 + 2.0 $$ | 15.8 + 5.2 | 19.9 + 4.0 | 20.1 + 4.1 |
| Polyunsaturated Fat intake (g/day) (PFC%) | 7.5 + 6.0 | 5.3 + 4.9 ## | 5.4 + 3.2 ## | 8.8 + 4.2 | 4.4 + 2.2 | 4.7 + 0.9 |
| Physical activity (min/week) | 121.2 + 12.1 | 127.8 + 12.5 | 130.1 + 9.9 | 125.9 + 4.2 | 132.1 + 11.2 | 133.2 + 10.2 |
PTC: Percentage of total calories; PFC: Percentage of fat calories. Statistical differences p < 0.05, in each genotype group (* Daily Calorie intake, $ Daily Carbohydrate intake, # Daily fat intake, & Daily protein intake, ** Saturated fat intake, $$ monounsaturated fat intake, ## Polyunsaturated fat intake).
Adiposity parameters and pressure at three times (basal and 3 and 9 months after the intervention) (mean ± SD).
| TT ( | TC + CC ( | |||||
|---|---|---|---|---|---|---|
| 0 Time | 3 Months | 9 Months | 0 Time | 3 Months | 9 Months | |
| BMI | 40.8 ± 2.1 | 38.3 ± 3.2 * | 36.1 ± 1.1 * | 40,6 ± 2.3 | 38.4 ± 2.1 * | 36.2 ± 1.0 * |
| Weight (kg) | 91.4 ± 3.2 | 86.9 ± 2.0 $ | 84.8 ± 2.0 $ | 90.9 ± 2.1 | 86.8 ± 2.0 $ | 84.5 ± 2.1 $ |
| Fat mass (kg) | 36.3 ± 1.1 | 33.1 ± 1.0 # | 31.2 ± 1.1 # | 35.9± 1.2 | 33.0± 1.8 # | 30.9 ± 1.8 # |
| WC (cm) | 111.7 ± 4.3 | 107.1 ± 3.1 & | 105.5 ± 3.0 & | 110.8 ± 6.0 | 107.6 ± 4.1 & | 104.9 ± 3.1 & |
| SBP (mmHg) | 127.0 ± 3.0 | 123.1 ± 3.1 ** | 122.8 ± 4.0 ** | 126.9± 4.1 | 122.1 ± 3.1 ** | 121.7 ± 2.9 ** |
| DBP (mmHg) | 81.3 ± 3.1 | 78.8 ± 4.1 | 79.1 ± 4.0 | 81.4 ± 3.0 | 78.1 ± 3.0 | 78.9 ± 4.1 |
BMI: body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, waist circumference; Statistical differences p < 0.05, in each genotype group with basal value (* BMI, $ Weight, # fat mass, & WC, ** SBP). No statistical differences between genotype groups.
Biochemical parameters at three times (basal and 3 and 9 months after the intervention) (mean ± SD). (mean ± SD).
| TT ( | TC + CC ( | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Glucose (mg/dL) | 103.8 ± 4.0 | 100.8 ± 3.1 | 99.8 ± 4.2 | 101.3 ± 6.0 | 99.9 ± 4.2 | 98.7 ± 4.1 |
| Total ch. (mg/dL) | 208.8 ± 4.6 | 195.2 ± 4.1 $ | 193.1 ± 3.1 $ | 208.7 ± 4.1 | 194.1 ± 3.1 $ | 192.1 ± 3.0 $ |
| LDL-ch. (mg/dL) | 137.2 ± 8.1 | 120.8 ± 2.2 # | 118.1 ± 4.0 # | 140.5 ± 3.9 | 122.5 ± 4.2 # | 118.9 ± 3.1 # |
| HDL-ch. (mg/dL) | 55.8 ± 1.6 | 54.7 ± 1.9 | 55.1 ± 1.2 | 55.9 ± 2.1 | 55.5 ± 1.3 | 56.1 ± 1.2 |
| TG (mg/dL) | 123.2 ± 11.0 | 110.9 ± 9.2 * | 104.1 ± 6.2 * | 143.1 ± 10.2 x | 140.8 ± 4.1 x | 139.1 ± 7.8 x |
| Insulin (mUI/L) | 10.8 ± 2.1 | 9.2 ± 1.3 & | 7.0 ± 1.0 & | 12.3 ± 2.1 | 10.8 ± 2.2 | 11.0 ± 2.3 |
| HOMA-IR | 3.7 ± 1.0 | 2.1 ± 0.9 ** | 1.5 ± 0.7 ** | 3.9 ± 0.8 | 3.5 ± 1.1 | 3.6 ± 1.2 |
| CRP (mg/dL) | 4.3 ± 1.0 | 4.3 ± 1.3 | 4.2 ± 1.1 | 4.4 ± 2.1 | 4.5 ± 1.3 | 4.3 ± 1.1 |
HOMA-IR (homeostasis model assessment). CRP (C-reactive protein). Statistical differences p < 0.05, in each genotype group with basal values (total cholesterol $, LDL cholesterol #, triglycerides *, insulin &, HOMA IR **). Statistical differences p < 0.05, between genotype groups (triglycerides x).
Circulating adipocytokines at three times (basal and 3 and 9 months after the intervention) (mean ± SD). (mean ± S.D).
| TT ( | TC + CC ( | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Adiponectin (ng/mL) | 4.8 ± 1.0 | 4.7 ± 2.0 | 4.9 ± 1.8 | 4.5 ± 2.0 | 4.4 ± 1.3 | 4.7 ± 1.2 |
| Resistin (ng/mL) | 39.1 ± 5.0 | 68.1 ± 4.2 $ | 63.1 ± 4.1 $ | 34.9 ± 4.1 | 67.2 ± 4.2 $ | 66.1 ± 3.1 $ |
| Leptin(ng/mL) | 88.1 ± 8.1 | 71.2 ± 4.1 * | 68.9 ± 4.1 * | 89.1 ± 8.1 | 70.1 ± 3.1 * | 69.9 ± 6.1 * |
| Ratio Adiponectin/leptin | 0.36 ± 0.2 | 0.92 ± 0.1 # | 0.91 ± 0.1 # | 0.18 ± 0.1 | 0.92 ± 0.3 # | 0.93 ± 0.2 # |
Statistical differences p < 0.05, in each genotype group (* leptin $ adiponectin, # ratio adiponectin/leptin). No statistical differences between genotype groups.